Our Location

304 North Cardinal St.
Dorchester Center, MA 02124

Alecnib(150mg)-Alectinib

Generic Identity: Alectinib

Manufacturer: Everst Pharmaceutical ltd.

Quantity: 56 Tablets

Originator: Alecensa by Roche’s Chugai

To order:

Whats app & Wechat: +8801304498958

email: medsforcancer8@gmail.com

Category:

Alecnib(150mg)-Alectinib : Package Insert

Description

Alecnib(150mg)-Alectinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Alecnib(150mg) is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

Alecnib(150mg) is a second-generation oral drug used to treat non-small cell lung cancer by selectively inhibiting the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase, which causes cell proliferation. This prevents phosphorylation and reduces tumor cell viability.

  • Alecnib(150mg) is a prescription medicine used to treat adults with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC).
  • Alecnib(150mg) is a type of targeted therapy that works by blocking the ALK protein.
  • By blocking the ALK protein, Alecnib(150mg) can help to shrink tumors and slow the growth of cancer.
  • Alecnib(150mg) is a type of cancer medication used to treat non-small cell lung cancer (NSCLC) in people who have an error in their anaplastic lymphoma kinase (ALK) gene.
  • Alecnib(150mg) is a ALK tyrosine kinase inhibitor.

Indications

Alecnib(150mg)-Alectinib is indicated for:

  • First-line treatment of adult patients with ALK-positive, advanced non-small cell lung cancer (NSCLC).
  • Treatment of adult patients with ALK-positive, metastatic NSCLC who have failed crizotinib.
  • Treatment of adult patients with ALK-positive, metastatic NSCLC who have progressed following treatment with crizotinib and at least one other ALK inhibitor.
  • This indication is approved under accelerated approval based on tumor response rate and duration of response.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Mechanism of Action

Alecnib(150mg)-Alectinib is a second-generation oral drug used to treat non-small cell lung cancer (NSCLC) by selectively inhibiting the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. This prevents phosphorylation and activation of STAT3 and AKT, reducing tumor cell viability. Both Alecnib(150mg) and its metabolite M4 show similar activity against multiple mutant forms of ALK.

  • Alecnib(150mg) binds to the ALK protein and blocks its activity.
  • This prevents ALK from signaling to cells to grow and divide.
  • As a result, Alecnib(150mg) helps to shrink tumors and slow the spread of cancer.

Side Effects

The most common side effects of Alecnib(150mg) include:

  • Fatigue
  • Nausea and vomiting
  • Diarrhea
  • Constipation
  • Muscle and joint pain
  • Rash
  • Decreased appetite
  • Weight loss
  • Vision changes
  • Liver problems

Less common but more serious side effects of Alecnib(150mg) include:

  • Interstitial lung disease (ILD)
  • Pneumonitis
  • Heart problems
  • Nervous system problems
  • Pancreatitis
  • Liver failure
  • Death

It is important to note that not everyone who takes Alecnib(150mg)-Alectinib will experience side effects, and the severity of side effects can vary from person to person. If you are taking Alecnib(150mg), be sure to talk to your doctor about the potential side effects and how to manage them.

Here are some additional things to keep in mind about Alectinib side effects:

  • Many of the side effects of Alecnib(150mg) are mild and go away on their own.
  • Some side effects can be managed with over-the-counter medications.
  • Other side effects may require prescription medication or treatment from a doctor.
  • If you experience any serious side effects, be sure to contact your doctor right away.

Dosage and Administration

The recommended dosage of Alectinib is 600 mg orally twice daily, with or without food. Alecnib(150mg)-Alectinib should be taken until disease progression or unacceptable toxicity.

The recommended dosage of Alecnib(150mg) in patients with severe hepatic impairment (Child-Pugh C) is 450 mg orally twice daily.

If a dose of Alecnib(150mg) is missed, the next dose should be taken as soon as possible. If vomiting occurs after taking a dose of Alectinib, the next dose should be taken at the scheduled time.

Alecnib(150mg) capsules should be swallowed whole with water. Do not open or dissolve the capsules.

Alecnib(150mg)-Alectinib Price

Price of the Alectinib varies country to country and also depends on manufacturer brand.

Alecnib(150mg) is manufactured in Bangladesh by Everest Pharmaceuticals is a renowned name in pharmaceutical industry. This medicine is available for everyone in the world contact with us to know the price because it changes with time.

Alecnib(150mg)-Alectinib FDA Approval

Alectinib was approved by the FDA on December 11, 2015, for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or who are intolerant of crizotinib.

On November 6, 2017, the FDA granted regular approval to alectinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC, as detected by an FDA-approved test.

The FDA’s approval of alectinib was based on the results of two clinical trials. In the first trial, alectinib was shown to be more effective than crizotinib in shrinking tumors and improving survival in patients with ALK-positive NSCLC whose disease had progressed on crizotinib. In the second trial, alectinib was shown to be effective in treating patients with ALK-positive NSCLC who were intolerant of crizotinib.

Life Expectancy of Alecnib(150mg)-Alectinib

Alecnib(150mg) treatment has shown significant improvements in life expectancy for patients with ALK-positive NSCLC. In the ALEX clinical trial, patients treated with Alecnib(150mg) had a median overall survival of 62.5 months, compared to 34.8 months in the crizotinib arm. The J-ALEX study also showed a significant improvement in OS for patients treated with Alecnib(150mg), with a median of 68.6 months. These results suggest that Alecnib(150mg) is an effective treatment for ALK-positive NSCLC, and patients treated with Alecnib(150mg) can expect to live longer than those treated with other therapies.

Alectinib vs Brigatinib

Brigatinib and Alecnib(150mg) are both tyrosine kinase inhibitors (TKIs) that are used to treat ALK-positive non-small cell lung cancer (NSCLC). They are both effective in shrinking tumors and improving survival, but there are some key differences between the two drugs.

Mechanism of action

Brigatinib and Alecnib(150mg) both work by blocking the activity of the anaplastic lymphoma kinase (ALK) protein. ALK is a receptor tyrosine kinase that plays a role in cell growth and differentiation. When ALK is mutated or overexpressed, it can lead to uncontrolled cell growth and cancer.

Brigatinib is a more potent inhibitor of ALK than Alecnib(150mg). It also blocks the activity of other tyrosine kinases, such as ROS1 and MET, which can lead to additional benefits in some patients.

Efficacy

Brigatinib and Alecnib(150mg) are both effective in shrinking tumors and improving survival in patients with ALK-positive NSCLC. In the Phase III ALTA trial, brigatinib was shown to be more effective than alectinib in shrinking tumors in patients with ALK-positive NSCLC who had progressed on or were intolerant of crizotinib. The median progression-free survival (PFS) for patients in the brigatinib arm was 11.2 months, compared to 6.8 months for patients in the alectinib arm.

Compared to crizotinib, Alecnib(150mg) was shown in the Phase III ALEX trial to be more effective in shrinking tumors in patients with ALK-positive NSCLC who had not previously been treated with a TKI. The median PFS for patients in the Alecnib(150mg) arm was 12.5 months, compared to 7.2 months for patients in the crizotinib arm.

Safety

Both brigatinib and Alecnib(150mg) can cause side effects, the most common of which are fatigue, nausea, vomiting, diarrhea, and constipation. Brigatinib is more likely to cause interstitial lung disease (ILD) than Alecnib(150mg).

See our other anti-cancer medicine Lorbrexen-100mg, Alecinix-150mg, Rizonib-250mg, Crizotinib-250mg, Tagrix-80mg

Follow us on Instagram to get update.

FAQs about Alecnib(150mg)-Alectinib

How Long after chemoradiation Alectinib to start?

Alecnib(150mg)'s timing after chemoradiation depends on factors like the patient's health, response to chemoradiation, and any side effects. Doctors typically start treatment with alectinib within a few weeks to a few months. A doctor's recommendation is based on the patient's overall health, response to chemoradiation, and any side effects experienced. Assessments may include blood tests, imaging tests, and a physical exam. The doctor will also evaluate the patient's response to chemoradiation, including reviewing imaging tests and discussing symptoms. The best approach is to consult a doctor to determine the best timing for Alectinib treatment.

Is Alectinib a chemotherapy?

Alecnib(150mg) is a targeted therapy drug that targets the anaplastic lymphoma kinase (ALK) protein, a receptor tyrosine kinase involved in cell growth and differentiation. It is less harmful to healthy cells than chemotherapy drugs, as it targets specific molecules involved in cancer cell growth and survival. Mutations or overexpression of ALK can lead to uncontrolled cell growth and cancer.

How long does it takes for Alectinib to work?

Alecnib(150mg)'s effectiveness depends on the cancer stage, patient's health, and treatment response. Clinical trials show it shrinks tumors and improves survival rates in ALK-positive NSCLC patients. However, not everyone responds, and it's crucial to be patient. Regular imaging tests help monitor response and adjust dosage as prescribed by a doctor.

 

Reviews

There are no reviews yet.

Be the first to review “Alecnib(150mg)-Alectinib”